GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nu-Med Plus Inc (OTCPK:NUMD) » Definitions » ROC (Joel Greenblatt) %

Nu-Med Plus (Nu-Med Plus) ROC (Joel Greenblatt) % : 0.00% (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Nu-Med Plus ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Nu-Med Plus's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for Nu-Med Plus's ROC (Joel Greenblatt) % or its related term are showing as below:

During the past 13 years, Nu-Med Plus's highest ROC (Joel Greenblatt) % was 36679.25%. The lowest was -12139.73%. And the median was -1290.00%.

NUMD's ROC (Joel Greenblatt) % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -2.13
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Nu-Med Plus's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Nu-Med Plus ROC (Joel Greenblatt) % Historical Data

The historical data trend for Nu-Med Plus's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nu-Med Plus ROC (Joel Greenblatt) % Chart

Nu-Med Plus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,323.38 -1,212.77 -540.72 -1,290.00 -

Nu-Med Plus Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nu-Med Plus's ROC (Joel Greenblatt) %

For the Medical Devices subindustry, Nu-Med Plus's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nu-Med Plus's ROC (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nu-Med Plus's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Nu-Med Plus's ROC (Joel Greenblatt) % falls into.



Nu-Med Plus ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.006) - (0.06 + 0 + 0)
=-0.054

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.003) - (0.078 + 0 + 0)
=-0.075

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Nu-Med Plus for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.084/( ( (0 + max(-0.054, 0)) + (0 + max(-0.075, 0)) )/ 1 )
=-0.084/( ( 0 + 0 )/ 1 )
=-0.084/0
= %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nu-Med Plus  (OTCPK:NUMD) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Nu-Med Plus ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Nu-Med Plus's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nu-Med Plus (Nu-Med Plus) Business Description

Traded in Other Exchanges
N/A
Address
640 Belle Terre Road, Building 2 E Port, Jefferson, NY, USA, 11777
Nu-Med Plus Inc is an medical device company principally engaged in the design, innovation, development, enhancement, and commercialization of beginning, early, and selective later-stage quality medical devices. It focuses on the formulation of Nitric Oxide powder, which is a desktop generator device which delivers inhaled Nitric Oxide to replace expensive pressurized canisters and a mobile rechargeable device to deliver inhaled Nitric Oxide gas to offer solutions to hospitals, health systems and medical community throughout the world.
Executives
William C Hayde director, officer: CEO 76 CLIFF ROAD, BELLE TERRE NY 11777
Wendy P. Smith 10 percent owner P. O. BOX 1374, SALT LAKE CITY UT 84110
Brett J. Earl director, officer: VP of Medical Marketing P.O. BOX 729, MORGAN UT 84050
Mark Edward Christensen officer: CFO, Sec, Treas, Prin Acct Off 455 E. 500 S., SUITE 207, SALT LAKE CITY UT 84111
Thomas A Tait 10 percent owner 514 AMERICAS WAY #5556, BOX ELDER SD 57719
Craig Morrison director, 10 percent owner, officer: Vice President of Technology 975 NORTH TERRACE DRIVE, PROVO UT 84604
William G Moon director, 10 percent owner, officer: Vice President of Operations 1266 SOUTH 1380 WEST, OREM UT 84058
Jeffrey Lynn Robins director, 10 percent owner, officer: CEO 455 EAST 500 SOUTH, SUITE #205, SALT LAKE CITY UT 84111